Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 59Neoplasms 6Neoplasm Metastasis 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 4Ovarian Neoplasms 3Neoplasms by Site 3Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteitis Deformans 1Neoplasms, Germ Cell and Embryonal 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5cemiplimab 4Cyclophosphamide 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × ribociclib × Clear all
NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
430 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡